Manufacturer
Takeda Pharmaceutical Company Limited.,
Contents
Vonoprazan
Indication
Gastric & duodenal ulcer; reflux esophagitis (erosive esophagitis). Maintenance treatment of reflux esophagitis (erosive esophagitis). Prevention of gastric or duodenal ulcer recurrence during NSAID administration. Adjunct to H pylori eradication associated w/ gastric & duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, stomach after endoscopic resection of early stage cancer or H pylori gastritis.
Instruction
May be taken with or without food.
Drug interaction
Interfered w/ absorption of drugs whose bioavailability is pH-dependent eg, atazanavir, nelfinavir. Increased blood conc w/ strong CYP3A4 inhibitors eg, clarithromycin. Increased conc w/ clarithromycin & amoxicillin regimen.
Malaysia
